Ayala Pharmaceuticals (ADXS) Competitors $0.04 +0.00 (+9.65%) As of 05/19/2025 03:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, AEZS, LIPO, and MTVAShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), Aeterna Zentaris (AEZS), Lipella Pharmaceuticals (LIPO), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Indaptus Therapeutics Genprex AIM ImmunoTech Chromocell Therapeutics Biofrontera Avalon GloboCare Soligenix Aeterna Zentaris Lipella Pharmaceuticals MetaVia Indaptus Therapeutics (NASDAQ:INDP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Does the MarketBeat Community favor INDP or ADXS? Indaptus Therapeutics received 13 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Ayala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% Do institutionals and insiders believe in INDP or ADXS? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, INDP or ADXS? Indaptus Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Is INDP or ADXS more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Ayala Pharmaceuticals N/A N/A N/A Which has higher earnings and valuation, INDP or ADXS? Indaptus Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.26Ayala Pharmaceuticals$3.24M0.49-$48.07M-$7.980.00 Does the media prefer INDP or ADXS? In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.50 beat Ayala Pharmaceuticals' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Very Positive Ayala Pharmaceuticals Neutral Do analysts rate INDP or ADXS? Indaptus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 2,136.84%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Indaptus Therapeutics is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIndaptus Therapeutics beats Ayala Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio0.008.9226.7619.71Price / Sales0.49252.24389.94117.54Price / CashN/A65.8538.2534.62Price / Book-0.026.466.804.50Net Income-$48.07M$143.98M$3.23B$248.18M7 Day PerformanceN/A2.03%1.52%0.23%1 Month PerformanceN/A4.11%10.04%12.39%1 Year PerformanceN/A-2.87%16.73%7.07% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.04+9.6%N/A-87.5%$1.60M$3.24M0.0020News CoverageAnalyst ForecastGap UpINDPIndaptus Therapeutics3.3455 of 5 stars$0.42+3.9%$8.50+1,941.8%-83.8%$6.68MN/A-0.246Gap DownGNPXGenprex0.9206 of 5 stars$0.28-3.3%$10.00+3,523.2%-88.2%$6.67MN/A0.0020Gap UpAIMAIM ImmunoTech1.4305 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.7%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.08-1.9%N/A-46.8%$6.59MN/A-0.734Gap DownBFRIBiofrontera2.7003 of 5 stars$0.68-1.8%$7.00+925.6%-42.1%$6.45M$37.32M-0.3070Earnings ReportAnalyst ForecastAnalyst RevisionGap UpALBTAvalon GloboCare0.5545 of 5 stars$3.87-0.5%N/A-11.0%$6.39M$1.33M-0.195Positive NewsUpcoming EarningsSNGXSoligenix0.9935 of 5 stars$1.96-1.3%N/A-68.8%$6.38M$840,000.00-0.2620AEZSAeterna ZentarisN/A$3.55+5.0%N/A-57.0%$6.37M$2.37M-0.2420Analyst ForecastLIPOLipella Pharmaceuticals0.9501 of 5 stars$2.45+1.9%N/A-49.7%$6.23M$536,357.00-0.584Positive NewsMTVAMetaVia1.8101 of 5 stars$0.70-3.9%$12.00+1,612.6%N/A$6.07MN/A0.008News CoverageAnalyst Forecast Related Companies and Tools Related Companies Indaptus Therapeutics Alternatives Genprex Alternatives AIM ImmunoTech Alternatives Chromocell Therapeutics Alternatives Biofrontera Alternatives Avalon GloboCare Alternatives Soligenix Alternatives Aeterna Zentaris Alternatives Lipella Pharmaceuticals Alternatives MetaVia Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXS Stock Free ADXS Stock Alerts